Is there a clinical benefit in testing for UGT1A1*28 prior to irinotecan therapy? Background: CD133 has been described as a stem cell marker in colorectal cancer and is associated with higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback